Diana Behrens, Ulrike Pfohl, Theresia Conrad, Michael Becker, Bernadette Brzezicha, Britta Büttner, Silvia Wagner, Cora Hallas, Rita Lawlor, Vladimir Khazak, Michael Linnebacher, Thomas Wartmann, Iduna Fichtner, Jens Hoffmann, Mathias Dahlmann, Wolfgang Walther
Patient-derived xenograft (PDX) tumor models are essential for identifying new biomarkers, signaling pathways and novel targets, to better define key factors of therapy response and resistance mechanisms. Therefore, this study aimed at establishing pancreas carcinoma (PC) PDX models with thorough molecular characterization, and the identification of signatures defining responsiveness toward drug treatment. In total, 45 PC-PDXs were generated from 120 patient tumor specimens and the identity of PDX and corresponding patient tumors was validated...
December 8, 2023: Cancers